129 related articles for article (PubMed ID: 15548683)
1. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.
Leu YW; Yan PS; Fan M; Jin VX; Liu JC; Curran EM; Welshons WV; Wei SH; Davuluri RV; Plass C; Nephew KP; Huang TH
Cancer Res; 2004 Nov; 64(22):8184-92. PubMed ID: 15548683
[TBL] [Abstract][Full Text] [Related]
2. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
[TBL] [Abstract][Full Text] [Related]
3. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
Hinshelwood RA; Huschtscha LI; Melki J; Stirzaker C; Abdipranoto A; Vissel B; Ravasi T; Wells CA; Hume DA; Reddel RR; Clark SJ
Cancer Res; 2007 Dec; 67(24):11517-27. PubMed ID: 18089780
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity.
Deblois G; Hall JA; Perry MC; Laganière J; Ghahremani M; Park M; Hallett M; Giguère V
Cancer Res; 2009 Aug; 69(15):6149-57. PubMed ID: 19622763
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer.
Li L; Lee KM; Han W; Choi JY; Lee JY; Kang GH; Park SK; Noh DY; Yoo KY; Kang D
Hum Mol Genet; 2010 Nov; 19(21):4273-7. PubMed ID: 20724461
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Travaglini L; Vian L; Billi M; Grignani F; Nervi C
Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic information and estrogen receptor alpha expression in breast cancer.
Giacinti L; Claudio PP; Lopez M; Giordano A
Oncologist; 2006 Jan; 11(1):1-8. PubMed ID: 16401708
[TBL] [Abstract][Full Text] [Related]
10. Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.
Lin Z; Reierstad S; Huang CC; Bulun SE
Cancer Res; 2007 May; 67(10):5017-24. PubMed ID: 17510434
[TBL] [Abstract][Full Text] [Related]
11. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.
Rody A; Holtrich U; Solbach C; Kourtis K; von Minckwitz G; Engels K; Kissler S; Gätje R; Karn T; Kaufmann M
Endocr Relat Cancer; 2005 Dec; 12(4):903-16. PubMed ID: 16322330
[TBL] [Abstract][Full Text] [Related]
12. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
Mc Cormack O; Chung WY; Fitzpatrick P; Cooke F; Flynn B; Harrison M; Fox E; Gallagher E; McGoldrick A; Dervan PA; McCann A; Kerin MJ
Breast Cancer Res Treat; 2008 Sep; 111(1):45-53. PubMed ID: 17896177
[TBL] [Abstract][Full Text] [Related]
13. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
14. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Wolf I; O'Kelly J; Rubinek T; Tong M; Nguyen A; Lin BT; Tai HH; Karlan BY; Koeffler HP
Cancer Res; 2006 Aug; 66(15):7818-23. PubMed ID: 16885386
[TBL] [Abstract][Full Text] [Related]
15. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway.
Sauvé K; Lepage J; Sanchez M; Heveker N; Tremblay A
Cancer Res; 2009 Jul; 69(14):5793-800. PubMed ID: 19584281
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer.
Chavey C; Mühlbauer M; Bossard C; Freund A; Durand S; Jorgensen C; Jobin C; Lazennec G
Mol Pharmacol; 2008 Nov; 74(5):1359-66. PubMed ID: 18669446
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Hara Y; Kobayashi S; Iwase H
Breast Cancer Res Treat; 2005 Nov; 94(1):11-6. PubMed ID: 16172792
[TBL] [Abstract][Full Text] [Related]
18. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer.
Yan L; Yang X; Davidson NE
J Mammary Gland Biol Neoplasia; 2001 Apr; 6(2):183-92. PubMed ID: 11501578
[TBL] [Abstract][Full Text] [Related]
19. Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer.
Parl FF
Pharmacogenomics J; 2003; 3(5):251-3. PubMed ID: 14583793
[No Abstract] [Full Text] [Related]
20. Epigenetic regulation of estrogen signaling in breast cancer.
Hervouet E; Cartron PF; Jouvenot M; Delage-Mourroux R
Epigenetics; 2013 Mar; 8(3):237-45. PubMed ID: 23364277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
